• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Praxis Precision Medicines Inc (NQ: PRAX )

    64.38 -0.39 (-0.60%)
    Streaming Delayed Price Updated: 11:23 AM EDT, Oct 9, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Praxis Precision Medicines Inc

    < Previous 1 2 3 4 5 6 Next >
    Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    Praxis Precision Medicines to Participate in Upcoming Investor Conferences
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    Forecasting The Future: 14 Analyst Projections For Praxis Precision Medicine
    Via Benzinga
    What 6 Analyst Ratings Have To Say About Praxis Precision Medicine
    Via Benzinga
    Demystifying Praxis Precision Medicine: Insights From 7 Analyst Reviews
    Via Benzinga
    Philip Morris International To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Wednesday
    Via Benzinga
    Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug
    Praxis Precision Medicines reports positive Phase 2 EMBOLD study results for relutrigine in treating SCN2A and SCN8A developmental and epileptic encephalopathy, showing significant seizure reduction... 
    Via Benzinga
    Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    These Analysts Increase Their Forecasts On Praxis Precision Medicines After Q2 Results
    Via Benzinga
    PRAX Stock Earnings: Praxis Precision Medicine Beats EPS, Misses Revenue for Q2 2024
    PRAX stock results show that Praxis Precision Medicine beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    Are We Having Fun Yet? Stocks Sell Off On Massive Volume
    In this video, I review the overall market, my game-plan with the indices, how our largest swings are holding up, and the stocks on my radar. 
    Via Talk Markets
    Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
    The companies are no longer developing their drug for essential tremor treatment. 
    Via Investor's Business Daily
    Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Quarterly & Long-Term Portfolios For The Win
    What a day for Meta! I was planning to add to my position, but the volume was too low. I would have been shaken out of most of it for the swing before it could become this position trade. 
    Via Talk Markets
    Value Of Praxis Precision Medicines' Lead Program In Essential Tremor Alone Is Underappreciated: Analyst
    Needham rates Praxis Precision Medicines Buy with a $145 target. Key programs include ulixacaltamide for essential tremor (Phase 3 results expected in 2024) and PRAX-628 for focal seizures. 
    Via Benzinga
    Jazz Dives — And Takes Praxis With It — On Essential Tremor Drug Failure
    The companies are working on treatments for essential tremor, a tricky indication. 
    Via Investor's Business Daily
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Praxis Precision Medicines to Participate in Upcoming Investor Conferences
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    Critical Insights From Praxis Precision Medicine Analyst Ratings: What You Need To Know
    Via Benzinga
    PRAX Stock Earnings: Praxis Precision Medicine Misses EPS, Misses Revenue for Q1 2024
    PRAX stock results show that Praxis Precision Medicine missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
    Innovative design of ongoing Phase 3 clinical program expected to set precedent for future clinical trials in essential tremor 
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.